SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-23-004687
Filing Date
2023-03-30
Accepted
2023-03-30 08:08:32
Documents
15
Period of Report
2023-03-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20230329.htm   iXBRL 8-K 41061
2 EX-99.1 achv-ex991_6.htm EX-99.1 25066
3 GRAPHIC glvvy3kqwecw000003.jpg GRAPHIC 16366
4 GRAPHIC glvvy3kqwecw000001.jpg GRAPHIC 18627
  Complete submission text file 0001564590-23-004687.txt   248797

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA achv-20230329.xsd EX-101.SCH 5617
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20230329_lab.xml EX-101.LAB 20039
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20230329_pre.xml EX-101.PRE 11943
9 EXTRACTED XBRL INSTANCE DOCUMENT achv-8k_20230329_htm.xml XML 3674
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 23777228
SIC: 2835 In Vitro & In Vivo Diagnostic Substances